{
  "ticker": "LLY",
  "target_date": "2025-01-29",
  "actual_date": "2025-01-29",
  "collected_at": "2025-12-08T11:20:18.794171",
  "price": {
    "open": 801.02,
    "high": 803.13,
    "low": 793.08,
    "close": 798.1268920898438,
    "volume": 1827600,
    "change_1d_pct": -0.11,
    "change_7d_pct": 10.8,
    "change_30d_pct": 2.78
  },
  "technicals": {
    "rsi_14": 57.24,
    "sma_20": 767.74,
    "sma_50": 772.63,
    "macd": 2.164,
    "macd_signal": -3.898,
    "macd_histogram": 6.061,
    "bb_upper": 814.11,
    "bb_lower": 721.38,
    "price_vs_sma20_pct": 3.96,
    "price_vs_sma50_pct": 3.3,
    "volume_ratio": 0.48
  },
  "fundamentals": {
    "market_cap": 889791643648,
    "pe_ratio": 48.63131,
    "forward_pe": 43.802517,
    "price_to_book": 37.37067,
    "price_to_sales": 14.974666,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.74,
    "pct_from_52w_low": 59.12
  },
  "macro": {
    "spy": {
      "price": 596.58,
      "change_1d_pct": -0.45,
      "change_7d_pct": -0.21
    },
    "vix": {
      "level": 16.56,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.55
    },
    "dollar_index": {
      "level": 108.0
    },
    "gold": {
      "price": 2769.1
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly Stock's Correction Brings Opportunity",
      "source": "SeekingAlpha",
      "datetime": 1738157273,
      "summary": "Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.",
      "url": "https://finnhub.io/api/news?id=aa212201579fa1eae1e193e7410ec4c0c10bcb8218ee8f54b6f3b6c66cadc823"
    },
    {
      "headline": "Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions",
      "source": "DowJones",
      "datetime": 1738134000,
      "summary": "Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions",
      "url": "https://finnhub.io/api/news?id=f8def61af47522572cf5f66ae41408506a626ffacd78973ab3a3375991c968f6"
    },
    {
      "headline": "ClearBridge Appreciation Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1738131360,
      "summary": "US equities delivered positive gains in the fourth quarter and finished the 12-month period up 25% for the second year in a row. Read more here.",
      "url": "https://finnhub.io/api/news?id=8dc013d99ef520c7f5903fb80adbd52e4a90b613357ecd622efcf00be060f355"
    },
    {
      "headline": "ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1738122900,
      "summary": "The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=00c8dc44289fdc166f4a31d57b1af9002d4f44ce3b2eedcf50456b9cc61f0b6d"
    },
    {
      "headline": "Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider",
      "source": "SeekingAlpha",
      "datetime": 1738077110,
      "summary": "Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.",
      "url": "https://finnhub.io/api/news?id=635f70ede4cab57879dcdf69cd9a4237560cc58ffe2efc18c6c2479b43622855"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667469.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000016/xslF345X05/wk-form4_1737667469.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667411.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000014/xslF345X05/wk-form4_1737667411.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000012/xslF345X05/wk-form4_1737667361.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667303.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000010/xslF345X05/wk-form4_1737667303.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667237.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000008/xslF345X05/wk-form4_1737667237.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}